{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T18:18:41Z","timestamp":1790014721343,"version":"4.0.1"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T00:00:00Z","timestamp":1778889600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T00:00:00Z","timestamp":1778889600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Research Accounting Unit, University Competitive Research Fund, Mansoura University, Egypt, .","award":["Code No. MU-Med-22-36"],"award-info":[{"award-number":["Code No. MU-Med-22-36"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Biol Rep"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1007\/s11033-026-11881-0","type":"journal-article","created":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T07:44:21Z","timestamp":1778917461000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Pharmacogenetics and pharmacokinetics of immunosuppressants: clinical correlations and disease activity control in Egyptian female patients with lupus nephritis"],"prefix":"10.1007","volume":"53","author":[{"given":"Ahmed Yahia","family":"Elmowafy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salwa","family":"Elwasif","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rasha","family":"Shemies","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed Mansour","family":"Abdel-Rahman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahmoud M.","family":"Zakaria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sameha A.","family":"Omar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Randa","family":"El-Gamal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nehal M.","family":"Ramadan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7982-4210","authenticated-orcid":false,"given":"Hala Abdel","family":"Malek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,16]]},"reference":[{"key":"11881_CR1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25168981","volume":"25","author":"A Roveta","year":"2024","unstructured":"Roveta A, Parodi EL, Brezzi B, Tunesi F, Zanetti V, Merlotti G, Quaglia M (2024) Lupus nephritis from pathogenesis to new therapies: an update. Int J Mol Sci 25:8981. https:\/\/doi.org\/10.3390\/ijms25168981","journal-title":"Int J Mol Sci"},{"key":"11881_CR2","doi-asserted-by":"publisher","DOI":"10.1136\/lupus-2025-001535","volume":"12","author":"C Ye","year":"2025","unstructured":"Ye C, Liu B, Chen L, Zhang L, Zheng Y, Tang K et al (2025) Impact of body weight on mycophenolic acid population pharmacokinetics in paediatric lupus nephritis: a pharmacogenomic integration study. Lupus Sci Med 12:e001535. https:\/\/doi.org\/10.1136\/lupus-2025-001535","journal-title":"Lupus Sci Med"},{"key":"11881_CR3","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1097\/FPC.0000000000000026","volume":"24","author":"V Lamba","year":"2014","unstructured":"Lamba V, Sangkuhl K, Sanghavi K, Fish A, Altman RB, Klein TE (2014) PharmGKB summary: mycophenolic acid pathway. Pharmacogenet Genomics 24:73\u201379. https:\/\/doi.org\/10.1097\/FPC.0000000000000026","journal-title":"Pharmacogenet Genomics"},{"key":"11881_CR4","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijbiomac.2025.145484","volume":"319","author":"MY Shen","year":"2025","unstructured":"Shen MY, Liu YO, Wang JY, Yao FL, Miao YS, Zhang JB et al (2025) Bioactive constituents from ginger as human uridine-diphosphate glucuronosyltransferase 1A9 inhibitors: potential metabolic modulators of mycophenolic acid. Int J Biol Macromol 145484. https:\/\/doi.org\/10.1016\/j.ijbiomac.2025.145484","journal-title":"Int J Biol Macromol"},{"key":"11881_CR5","doi-asserted-by":"publisher","unstructured":"Reichel A, Lienau P (2015) Pharmacokinetics in drug discovery: an exposure-centred approach to optimising and predicting drug efficacy and safety. New approaches to drug discovery. pp 235\u2013260. https:\/\/doi.org\/10.1007\/164_2015_26","DOI":"10.1007\/164_2015_26"},{"key":"11881_CR6","doi-asserted-by":"publisher","unstructured":"Wuttiputhanun T, Naiyarakseree N, Udomkarnjananun S, Kittanamongkolchai W, Asada L, Chariyavilasku P, Avihingsanon Y (2024) Therapeutic drug monitoring of mycophenolic acid and clinical outcomes of lupus nephritis: a systematic review and meta-analysis. Lupus Sci Med 11:e001093. https:\/\/doi.org\/10.1136\/lupus-2023-001093","DOI":"10.1136\/lupus-2023-001093"},{"key":"11881_CR7","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1016\/j.gpb.2016.03.008","volume":"14","author":"S Ahmed","year":"2016","unstructured":"Ahmed S, Zhou Z, Zhou J, Chen SQ (2016) Pharmacogenomics of drug metabolizing enzymes and transporters: relevance to precision medicine. Genomics Proteomics Bioinformatics 14:298\u2013313. https:\/\/doi.org\/10.1016\/j.gpb.2016.03.008","journal-title":"Genomics Proteomics Bioinformatics"},{"key":"11881_CR8","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1080\/14622416.2024.2344430","volume":"25","author":"HY Yow","year":"2024","unstructured":"Yow HY, Ikawati M, Siswanto S, Hermawan A, Rahmat AK, Tan JSL, Ikawati Z (2024) Influence of genetic polymorphisms on pharmacokinetics and treatment response of mycophenolic acid: a scoping review. Pharmacogenomics 25:259\u2013288. https:\/\/doi.org\/10.1080\/14622416.2024.2344430","journal-title":"Pharmacogenomics"},{"key":"11881_CR9","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1007\/s00228-018-2599-x","volume":"75","author":"P \u0141uszczy\u0144ska","year":"2019","unstructured":"\u0141uszczy\u0144ska P, Pawi\u0144ski T, Kunicki PK, Durlik M, Augustyniak-Bartosik H, Hurkacz M (2019) Pharmacokinetics of free and total mycophenolic acid in adult lupus nephritis patients\u2014implications for therapeutic drug monitoring. Eur J Clin Pharmacol 75:371\u2013379. https:\/\/doi.org\/10.1007\/s00228-018-2599-x","journal-title":"Eur J Clin Pharmacol"},{"key":"11881_CR10","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1016\/j.kint.2024.10.018","volume":"107","author":"AS De Vriese","year":"2025","unstructured":"De Vriese AS, Sethi S, Fervenza FC (2025) Lupus nephritis: redefining the treatment goals. Kidney Int 107:198\u2013211. https:\/\/doi.org\/10.1016\/j.kint.2024.10.018","journal-title":"Kidney Int"},{"key":"11881_CR11","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1124\/dmd.32.8.775","volume":"32","author":"O Bernard","year":"2004","unstructured":"Bernard O, Guillemette C (2004) The main role of UGT1A9 in the hepatic metabolism of mycophenolic acid and the effects of naturally occurring variants. Drug Metab Dispos 32:775\u2013778. https:\/\/doi.org\/10.1124\/dmd.32.8.775","journal-title":"Drug Metab Dispos"},{"key":"11881_CR12","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1080\/14397595.2019.1623435","volume":"30","author":"T Kiyokawa","year":"2020","unstructured":"Kiyokawa T, Hanaoka H, Iida H, Ishimori K, Takakuwa Y, Okazaki T et al (2020) High plasma mycophenolate acid concentration in the early phase of induction therapy predicts good renal outcome in lupus nephritis. Mod Rheumatol 30:517\u2013524. https:\/\/doi.org\/10.1080\/14397595.2019.1623435","journal-title":"Mod Rheumatol"},{"key":"11881_CR13","doi-asserted-by":"publisher","DOI":"10.1186\/s40780-022-00271-w","volume":"9","author":"T Mizaki","year":"2023","unstructured":"Mizaki T, Nobata H, Banno S, Yamaguchi M, Kinashi H, Iwagaitsu S et al (2023) Population pharmacokinetics and limited sampling strategy for therapeutic drug monitoring of mycophenolate mofetil in Japanese patients with lupus nephritis. J Pharm Health Care Sci 9:1. https:\/\/doi.org\/10.1186\/s40780-022-00271-w","journal-title":"J Pharm Health Care Sci"},{"key":"11881_CR14","doi-asserted-by":"publisher","first-page":"223","DOI":"10.4078\/jrd.22.0006","volume":"29","author":"DJ Park","year":"2022","unstructured":"Park DJ, Joo YB, Bang SY, Lee J, Lee HS, Bae SC (2022) Predictive factors for renal response in lupus nephritis: a single-center prospective cohort study. J Rheum Dis 29:223\u2013231. https:\/\/doi.org\/10.4078\/jrd.22.0006","journal-title":"J Rheum Dis"},{"issue":"5","key":"11881_CR15","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1002\/jcph.1064","volume":"58","author":"M Okour","year":"2018","unstructured":"Okour M, Jacobson PA, Ahmed MA, Israni AK, Brundage RC (2018) Mycophenolic acid and its metabolites in kidney transplant recipients: a semimechanistic enterohepatic circulation model to improve estimating exposure. J Clin Pharmacol 58(5):628\u2013639. https:\/\/doi.org\/10.1002\/jcph.1064","journal-title":"J Clin Pharmacol"},{"key":"11881_CR16","doi-asserted-by":"publisher","first-page":"713","DOI":"10.2147\/PGPM.S295964","volume":"14","author":"Q Shu","year":"2021","unstructured":"Shu Q, Fan Q, Hua B, Liu H, Wang S, Liu Y et al (2021) Influence of SLCO1B1 521TC, UGT2B7 802CT and IMPDH1\u2009\u2212\u2009106GA genetic polymorphisms on mycophenolic acid levels and adverse reactions in Chinese autoimmune disease patients. Pharmacogenomics and Personalized Medicine 14:713\u2013722. https:\/\/doi.org\/10.2147\/PGPM.S295964","journal-title":"Pharmacogenomics and Personalized Medicine"},{"key":"11881_CR17","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1007\/s10157-010-0270-7","volume":"14","author":"EM El-Shafey","year":"2010","unstructured":"El-Shafey EM, Abdou SH, Shareef MM (2010) Is mycophenolate mofetil superior to pulse intravenous cyclophosphamide for induction therapy of proliferative lupus nephritis in Egyptian patients? Clin Exp Nephrol 14:214\u2013221. https:\/\/doi.org\/10.1007\/s10157-010-0270-7","journal-title":"Clin Exp Nephrol"},{"key":"11881_CR18","doi-asserted-by":"publisher","DOI":"10.1136\/lupus-2017-000253","volume":"5","author":"J Tian","year":"2018","unstructured":"Tian J, Luo Y, Wu H, Long H, Zhao M, Lu Q (2018) Risk of adverse events from different drugs for SLE: a systematic review and network meta-analysis. Lupus Sci Med 5:e000253. https:\/\/doi.org\/10.1136\/lupus-2017-000253","journal-title":"Lupus Sci Med"}],"container-title":["Molecular Biology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-026-11881-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11033-026-11881-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-026-11881-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T07:44:22Z","timestamp":1778917462000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11033-026-11881-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,16]]},"references-count":18,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,12]]}},"alternative-id":["11881"],"URL":"https:\/\/doi.org\/10.1007\/s11033-026-11881-0","relation":{},"ISSN":["0301-4851","1573-4978"],"issn-type":[{"value":"0301-4851","type":"print"},{"value":"1573-4978","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,16]]},"assertion":[{"value":"17 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All authors declared no conflict of interest. Only the corresponding author received a fund for conducting this study and the details of the fund was previously mentioned.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The study was approved by the local ethics committee and the institutional reviewing board, Faculty of Medicine, Mansoura University, Mansoura, Egypt; and the study was conducted in accordance with the Declaration of Helsinki (Protocol No. RP.26.02.1052).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Written informed consents were signed by all participants.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}}],"article-number":"782"}}